China Dasheng Biotech (CDBT)

[LPK3]

Huge Development http://www.otcmarkets.com/financialReportViewer?symbol=CDBT&id=340744

Form 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2022
_______________________________
CHINA DASHENG BIOTECHNOLOGY CO.
(Exact name of registrant as specified in its charter)
_______________________________

Nevada 000-
(State or Other Jurisdiction (Commission
of Incorporation) File Number)
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers

A. Appointment of Micheal P. Nugent as a Director

On July 28, 2022, the board of directors of China Dasheng Biotechnology Co.. (the “Company”) appointed
Micheal P. Nugent, 59, as a director of the Company, with immediate effect.

For certain biographical and other information regarding Micheal P. Nugent, see the disclosure below under
Section C of this Item 5.02.

B. Resignation of officers and directors

On July 28, 2022, Frank I Igwealor resigned as a director of the Company, and as its President, Chief Executive
Officer and Treasurer advised the Company that he was resigning from the foregoing positions for personal
reasons and not because of any disagreement with the Company.
On July 28, 2022, Bryan Glass resigned as a director of the Company, and as its Secretary and advised the
Company that he was resigning from the foregoing positions for personal reasons and not because of any
disagreement with the Company.

C. Appointment of Financial Controller, President, and Chief Executive Officer

On July 28, 2022, the Company’s board of directors appointed Frank I Igwealor, 51, as the Financial Controller
of the Company.
On July 28, 2022, the Company’s board of directors appointed Micheal P. Nugent, 59, as the President and
Chief Executive Officer of the Company.

Micheal P. Nugent is a certified diesel fitter in Australia. Mr. Nugent has held senior executive positions and
directorships with public and private companies in the United States of America and Australia since 1995. His
technical and corporate experience is expected to assist the Company with its efforts to implement profitable
operations.

During the past five years, Mr. Nugent has held the following positions:

Position(s) Held From To Employer Business Operations

CEO 2003 Present Cycclone Magnetic Engines, Inc. Engine development and manufacture
director 2022 Present Cycclone Engine Developments Pty Ltd Engine development and manufacture
director 2022 Present Y Engine Developments Pty Ltd Engine development and manufacture
CEO 2011 Present Novagen Ingenium, Inc. Technology holding company
CEO 2021 Present AmerYcan Roadships. Inc. Transport infrastructure developer
CEO 2022 Present Roadships Australian Intermodal Marine
Lines Pty Ltd
Coastal shipping developer
director 2022 Present Allstate Transport Acquisitions Pty Ltd Transportation acquisitions
director 2022 Present Bronzelink Pty Ltd. Family holding company
Co Chairman 2022 Present Seven States Limited Australian Public transport and logistics
CEO 2009 2016 Tautachrome, Inc. Picture technology company

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CHINA DASHENG BIOTECHNOLOGY CO.
By Frank I Igwealor, Financial Controller


Date: July 28, 2022